SLC-391

News alerts, weekly reports and conference planners

Company:

SignalChem Lifesci, Sihuan Pharmaceutical

Drug class:

AXL inhibitor

Related drugs:

6ms

KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)

P1/2, N=98, Recruiting, SignalChem Lifesciences Corporation | Phase classification: P1b/2 --> P1/2

6 months ago

Phase classification

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • PD-L1 overexpression

Keytruda (pembrolizumab) • SLC-391

11ms

KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)

P1b/2, N=102, Recruiting, SignalChem Lifesciences Corporation | Not yet recruiting --> Recruiting

11 months ago

Enrollment open • Combination therapy • Metastases

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • PD-L1 overexpression

Keytruda (pembrolizumab) • SLC-391

over3years

[VIRTUAL] Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment (ASH 2020)

To test whether targeting of the AXL/GAS6 pathway is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed SLC-391, a novel, potent and selective AXL inhibitor. Importantly, the combination of AXL inhibition plus venetoclax treatment was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML, particularly patients with high AXL/GAS6 expression.

over 3 years ago

IO biomarker

AXL (AXL Receptor Tyrosine Kinase) • GAS6 (Growth arrest specific 6)

GAS6 elevation

Venclexta (venetoclax) • SLC-391